What is the significance of a serum alpha‑1‑antitrypsin level of 99 mg/dL (reference range 101‑187 mg/dL) and what follow‑up actions are recommended?

Serum Alpha-1-Antitrypsin Level of 99 mg/dL: Clinical Significance and Management

This borderline low alpha-1-antitrypsin (A1AT) level of 99 mg/dL requires immediate confirmatory testing with either DNA sequencing of the SERPINA1 gene or phenotyping to identify potential alpha-1 antitrypsin deficiency (AATD), as this value falls below the normal threshold and may represent a heterozygous or homozygous deficiency state that carries significant risk for emphysema and liver disease.

Immediate Diagnostic Action Required

The 2025 Canadian Thoracic Society guideline establishes a clear diagnostic pathway 1:

• Your serum A1AT of 99 mg/dL is below the reference range and mandates further testing
• The guideline recommends DNA sequencing of SERPINA1 gene exons 2-5 as the gold standard diagnostic test
• Alternative acceptable testing includes phenotyping (Pi typing) if genetic sequencing is unavailable

Why This Level Matters

A level of 99 mg/dL (approximately 0.99 g/L or 19 μmol/L) falls into a critical diagnostic zone:

• Severe deficiency is typically defined as <57.2 mg/dL (<11 μmol/L) 2
• However, intermediate phenotypes (MZ, SZ, SS) commonly present with levels between 57-140 mg/dL 3
• All patients with A1AT levels <100 mg/dL should undergo phenotyping 4

Clinical Implications by Genotype

Your actual risk depends entirely on your genetic variant:

If You Are Pi*ZZ (Severe Deficiency)

• Extremely high risk for early-onset panacinar emphysema, especially if you smoke or have smoked
• 30-40% risk of cirrhosis and liver cancer after age 50 3
• Eligible for augmentation therapy if you develop emphysema with airflow obstruction
• Mean age of symptom onset: 32-41 years in smokers, later in never-smokers 3

If You Are PiMZ or PiSZ (Intermediate Deficiency)

• Moderately increased risk for lung disease, particularly with smoking exposure
• Lower but present risk for liver disease
• May not qualify for augmentation therapy but requires lifestyle modification
• Family screening becomes important 1

If You Are Pi*MS or Other Variants

• Minimal to no increased disease risk in most cases
• Reassurance but continued monitoring if respiratory symptoms present

Required Follow-Up Testing Algorithm

Step 1: Confirm the A1AT level is not falsely low

• Repeat serum A1AT measurement with C-reactive protein (CRP) to exclude acute inflammation
• A1AT is an acute phase reactant that increases during inflammation; a low level during inflammation is particularly concerning 2, 5

Step 2: Obtain definitive genetic/protein characterization

• Preferred: DNA sequencing of SERPINA1 gene (exons 2-5) - this is invariable and definitive 1
• Alternative: Phenotyping by isoelectric focusing if sequencing unavailable
• Do NOT rely on targeted genotyping panels that only test for common variants (Z and S), as they miss rare pathogenic variants 1

Step 3: Clinical evaluation for organ involvement

• Pulmonary assessment:
  • Spirometry with bronchodilator response (look for FEV1/FVC <0.70)
  • High-resolution chest CT to evaluate for basilar panacinar emphysema 6
  • Diffusing capacity (DLCO) measurement
• Hepatic assessment:
  • Liver function tests (AST, ALT, alkaline phosphatase, bilirubin)
  • Abdominal ultrasound to evaluate for cirrhosis or hepatomegaly
  • Consider FibroScan or liver biopsy if abnormalities detected

Critical Preventive Measures (Start Immediately)

Regardless of final genotype, implement these interventions now 1:

1. Absolute smoking cessation if you smoke - this is non-negotiable and the single most important intervention
2. Avoid secondhand smoke, vaping, and inhaled cannabis
3. Avoid occupational/environmental lung irritants (dust, fumes, chemicals)
4. Update vaccinations: pneumococcal, influenza, COVID-19, pertussis
5. Maintain healthy weight and regular exercise
6. Pulmonary hygiene techniques if you have chronic cough or sputum

Family Screening Considerations

If you are confirmed to have a deficiency variant 1:

• All first-degree relatives (parents, siblings, children) should be tested
• Testing should include both serum A1AT level and genetic/phenotype characterization
• Early identification allows preventive counseling before disease develops

Common Diagnostic Pitfalls to Avoid

Pitfall 1: Assuming this is "borderline normal" and not pursuing further testing

• Studies show 43-57% of patients with A1AT <100 mg/dL never receive appropriate phenotyping 4
• This represents a missed opportunity for disease-modifying intervention

Pitfall 2: Ordering only targeted genotyping for Z and S alleles

• Misses rare variants that can cause deficiency with normal or near-normal A1AT levels (e.g., Pi*F variants with dysfunctional protein) 1

Pitfall 3: Delaying testing until symptoms develop

• Delayed diagnosis (average 5.3 years after symptom onset) is associated with worse survival and reduced quality of life 1
• Lung damage from AATD is irreversible 1

Pitfall 4: Testing during acute illness

• A1AT levels rise during inflammation, potentially masking deficiency
• Always check CRP and retest when clinically stable if elevated 2, 5

When to Consider Augmentation Therapy

You would only be eligible for augmentation therapy if ALL of the following criteria are met 2:

• Documented severe AATD genotype (typically Pi*ZZ) with A1AT <57.2 mg/dL
• CT-documented emphysema
• Impaired pulmonary function (typically FEV1 30-65% predicted)
• Receiving optimal COPD pharmacotherapy
• Not currently smoking

Your current level of 99 mg/dL would not typically qualify for augmentation therapy unless you have a rare dysfunctional variant, but this determination requires genetic confirmation first.

Timeline for Action

• Within 1 week: Repeat A1AT level with CRP, order SERPINA1 gene sequencing or phenotyping
• Within 2-4 weeks: Complete pulmonary function testing and chest imaging if not recently done
• Within 1 month: Obtain genetic counseling if deficiency variant confirmed
• Within 3 months: Complete family screening if you have a deficiency variant

The key message: A serum A1AT of 99 mg/dL is not normal and requires definitive genetic/phenotype characterization to determine your actual risk and guide management 1, 3, 4. Do not accept reassurance without complete diagnostic workup.